M.D. Anderson Cancer Center
To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.
Primary Objectives * To determine the safety of recommended dose by 20 participants including 10 relapsed/refractory participants (cohort 1) and 10 newly diagnosed participants (cohort 2). * To evaluate the overall response rate (combination of complete remission \[CR\] + complete remission with incomplete count recovery \[CRi) + complete remission with incomplete hematologic recovery \[CRh\]) of the combination of SC blinatumomab and revumenib in cohort 1 and cohort 2 (participants with MRD-only disease will not be included towards the overall response rate) * To evaluate event-free survival…
Eligibility Criteria • The following groups of participants will be eligible: * Participants \> 18 years of age with relapsed and/or refractory (defined as \>5% blasts in the peripheral blood or bone marrow) KMT2A-r B-cell ALL or * Participants \>18 years of age with persistent measurable residual disease by flow cytometry or next generation sequencing KMT2A-r B-cell ALL or * Newly diagnosed participants with KMT2A-r B-cell ALL \> 60 years old or unfit for intensive chemotherapy Unfit for intensive chemotherapy defined as: * ECOG \>2 * Severe cardiac disorder (e.g., congestive heart failur…
Given by po
Given by IV
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.